Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROBAXIN-750 vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
750 mg orally four times daily (total daily dose 3000 mg).
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic metabolism via dealkylation and hydroxylation, primarily by cytochrome P450 enzymes; metabolites are excreted renally.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
46-50% (primarily to albumin); binding is reversible and non-saturable at therapeutic concentrations.
30-35% bound to albumin.
0.9-1.5 L/kg (apparent Vd); clinical meaning: indicates extensive distribution into total body water and tissues, including muscle.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: about 50-75% (due to first-pass metabolism); bioavailability may vary with food (high-fat meal reduces rate but not extent).
Oral: 70-85% with high variability; intrathecal: 100%.
GFR 30-50 m L/min: administer 750 mg every 8 hours; GFR <30 m L/min: avoid use or administer with extreme caution; not studied in dialysis.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30-50% (e.g., 375-500 mg q6h); Child-Pugh Class C: contraindicated due to risk of hepatic encephalopathy.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for pediatric use; safety and efficacy not established.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initiate at low end of dosing range (e.g., 375 mg q6h) due to increased risk of sedation and falls; monitor renal function and CNS effects.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May cause drowsiness, dizziness, or blurred vision; patients should not operate machinery or drive until effects are known.,Use with caution in patients with known drug sensitivities or allergies.,May impair mental and/or physical abilities.,Seizures have been reported in patients with underlying seizure disorders or concurrent use of CNS depressants.,Serotonergic effects may occur with concurrent use of serotonergic drugs.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to methocarbamol or any component of the formulation.,Patients with known or suspected myasthenia gravis.,Patients with renal impairment (due to propylene glycol content in the injectable form; oral formulation does not contain propylene glycol but should be used cautiously).
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Take with food to reduce gastrointestinal upset. Avoid alcohol during treatment. No specific food restrictions.
No specific food interactions. Avoid alcohol due to additive CNS depression.
FDA Category C: Methocarbamol has shown fetal toxicity (reduced fetal weight, increased skeletal variations) in animal studies at doses similar to human doses. First trimester: Insufficient human data; avoid unless clearly needed. Second/third trimester: Limited data; potential for musculoskeletal effects. Use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Methocarbamol is excreted into breast milk in small amounts; M/P ratio not established. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for sedation or muscle weakness.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy. Use lowest effective dose; IV administration should be cautious due to increased plasma volume and risk of hypotension.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
ROBAXIN-750 (methocarbamol 750 mg) is a centrally acting muscle relaxant. It does not directly relax skeletal muscle but acts via CNS depression. Onset of action is ~30 minutes; peak effect at 2 hours. It is often used with rest, physical therapy, and NSAIDs. Contraindicated in myasthenia gravis. Doses exceeding 6 g/day may cause severe adverse effects. Tablet contains FD&C Yellow No. 5 (tartrazine), which may cause allergic reactions in susceptible individuals.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase sedation.,Notify your doctor if you have myasthenia gravis, allergies to tartrazine (FD&C Yellow No. 5), or if you are pregnant or breastfeeding.,May discolor urine (brown, black, or blue-green); this is harmless.,Do not stop suddenly; withdrawal symptoms (e.g., anxiety, insomnia) may occur with abrupt discontinuation after prolonged use.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROBAXIN-750 vs BACLOFEN, answered by our medical review team.
ROBAXIN-750 is a Skeletal Muscle Relaxant that works by Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROBAXIN-750 and BACLOFEN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROBAXIN-750 is: 750 mg orally four times daily (total daily dose 3000 mg).. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROBAXIN-750 and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROBAXIN-750 is classified as Category C. FDA Category C: Methocarbamol has shown fetal toxicity (reduced fetal weight, increased skeletal variations) in animal studies at doses similar to human doses. First trimester: Ins. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.